NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/03/2025
Voltar para busca
Dado oficial do USPTO
KYSO ANTIBODY MEDICINES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
KYSO ANTIBODY MEDICINES
ST13
US500000079356463Classe
1, 5, 42, 45
Pedido
79356463
Registro
7292415
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
28
Atualização mais recente
21/03/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 45
Data de depósito
10/08/2022
Data de registro
30/01/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/01/2024
Última transação
30/01/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
65
Localização do titular
DK
Examinador
FLETCHER, TRACY L
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Genmab A/S
Representantes
Max Vern Amster, Rothstein & Ebenstein LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Biological preparations for use in industry and science for in vitro and in vivo scientific and industrial research and development with regard to diseases; biochemical preparations for in vitro and in vivo scientific research purposes with regard to diseases; biochemical reagents used for non-medical purposes in the nature of in vitro and in vivo scientific and industrial research with regard to diseases; chemicals for use in biotechnological product development in the nature of in vitro and in vivo industrial product development with regard to diseases; active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of cancerautoimmune diseasesinflammatory disorders
Classe 5
Pharmaceutical and veterinary preparations including preparations based on antibodiesbi- and multi-specific antibodies as well as fragmentsderivatives and conjugates thereofpharmaceutical products for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; Pharmaceutical and veterinary preparationsincluding preparations based on antibodiesbi- and multi- specific antibodies as well as fragmentsderivatives and conjugates thereoffor the treatment of cancerautoimmune diseasesinflammatory disorders
Classe 42
Medicalscientific and biological research in the fields of antibodiesbi- and multi-specific antibodies as well as fragmentsderivatives and conjugates thereof and development of pharmaceutical products based on the same; chemical analysis; computer programmingprogramming of computers for the collection and processing of medical data for use in medical scientific researchdevelopment and therapy and scientific researchdevelopment and therapy with antibodies and bi- and multi- specific antibodies as well as fragmentsderivatives or conjugates of any of these
Classe 45
Legal services relating to the exploitation of patents and licensing of intellectual property in the field of medicine
Publicações
Histórico de despachos e eventos da marca no USPTO.
28 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
22/05/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/05/2024
FIMP
FINAL DISPOSITION PROCESSED
30/04/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/04/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/01/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
30/01/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
15/01/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
15/01/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
15/01/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
15/01/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/11/2023
PUBO
PUBLISHED FOR OPPOSITION
14/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/10/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/10/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
15/09/2023
RFNP
REFUSAL PROCESSED BY IB
24/05/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/05/2023
RFRR
REFUSAL PROCESSED BY MPU
03/05/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
15/03/2023
CNRT
NON-FINAL ACTION WRITTEN
14/03/2023
DOCK
ASSIGNED TO EXAMINER
13/03/2023
MAFR
APPLICATION FILING RECEIPT MAILED
09/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/12/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/12/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KYSO ANTIBODY MEDICINES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.